Immune checkpoint inhibitor-related myositis: From pathophysiology to treatment

Chandrasekhar Sundarrajan, Salman Bhai, Mazen M. Dimachkie

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

With rapid advances in immuno-oncology, immune checkpoint inhibitors (ICIs) are increasingly used for a broad array of malignancies. This has led to a novel spectrum of adverse effects including ICI-related myositis, a potentially life-threatening neuromuscular complication that must be diagnosed and treated promptly. Significant gaps exist in the current understanding of ICI-related myositis due to the rarity of the condition and the lack of evidence-based guidelines, prompting the need to synthesise the most relevant and recent published works in the field. This review provides a broad overview of ICI-related myositis with an emphasis on pathophysiology, epidemiology, clinical features, workup, management and future directions.

Original languageEnglish (US)
Pages (from-to)379-385
Number of pages7
JournalClinical and experimental rheumatology
Volume41
Issue number2
DOIs
StatePublished - Feb 2023

Keywords

  • autoimmunity
  • immune checkpoint inhibitors
  • immunotherapy
  • myositis
  • neoplasms

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitor-related myositis: From pathophysiology to treatment'. Together they form a unique fingerprint.

Cite this